A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB

Abstract

Waves of breakthrough infections by SARS-CoV-2 Omicron subvariants currently pose a global challenge to the control of the COVID-19 pandemic. We previously reported a pVAX1-based DNA vaccine candidate, pAD1002, that encodes a receptor-binding domain (RBD) chimera of SARS-CoV-1 and Omicron BA.1. In mouse and rabbit models, pAD1002 plasmid induced cross-neutralizing Abs against heterologous sarbecoviruses, including SARS-CoV-1 and SARS-CoV-2 wildtype, Delta and Omicron variants. However, these antisera failed to block the recent emerging Omicron subvariants BF.7 and BQ.1. To solve this problem, we replaced the BA.1 RBD-encoding DNA sequence in pAD1002 with that of BA.4/5. The resulting construct, namely pAD1016, elicited SARS-CoV-1 and SARS-CoV-2 RBD-specific IFN-γ+ cellular responses in BALB/c and C57BL/6 mice. More importantly, pAD1016 vaccination in mice, rabbits and pigs generated serum Abs capable of neutralizing pseudoviruses representing multiple SARS-CoV-2 Omicron subvariants including BA.2, BA.4/5, BF.7, BQ.1 and XBB. As a booster vaccine for inactivated SARS-CoV-2 virus preimmunization in mice, pAD1016 broadened the serum Ab neutralization spectrum to cover the Omicron BA.4/5, BF7 and BQ.1 subvariants. These preliminary data highlight the potential benefit of pAD1016 in eliciting neutralizing Abs against broad-spectrum Omicron subvariants in individuals previously vaccinated with inactivated prototype SARS-CoV-2 virus and suggests that pAD1016 is worthy of further translational study as a COVID-19 vaccine candidate.

A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers

“…With the new vaccine options, it is crucial to think of special populations, such as cancer patients, in advance and how such vaccines could be applied. [ 37 ] Additionally, neutralization breadth against different VOC correlates significantly with anti-SARS-CoV-2 S1 IgG Ab levels [ 24 , 28 ]. Surely, anti-SARS-CoV-2 S1 IgG Ab levels are easy to assess and reproduce and have been shown to be a valid surrogate for virus neutralization breadth [ 24 ].…”

COVID-19 Vaccination Reporting and Adverse Event Analysis in Taiwan

“…This includes investigating how long immunity lasts following the full initial vaccination series and subsequent booster doses. Moreover, it is essential to understand the robustness of vaccine-induced protection against the continuously evolving virus variants, which may differ in virulence and transmissibility [ 39 , 40 , 41 ].…”

A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety

“…Singular prefusion spike protein encoded copy or in conjunction with plasmid IL-12 transfection, based on the electroporation of plasmid DNA is conducted in-silico to produce a novel coronavirus vaccine (CORVax) [60] . On the 20th of August 2021, Zydus Cadila has been granted Emergency Use Authorization (EUA) by the Drug Controller General of India (DCGI) for ZyCoV-D, which is recognized as the world's first Plasmid DNA Vaccine developed to combat COVID-19 [59] , [60] . The administration of the vaccine ZyCoV-D is limited to the utilization of the PharmaJet Tropis® Needle-free Injection System.…”